Pomerantz Law Firm Investigates Cellectis S.A. Investor Claims
Pomerantz Law Firm is investigating claims on behalf of investors in Cellectis S.A. The probe concerns potential securities fraud and other unlawful business practices by the company and its officers.
New York – The law firm Pomerantz LLP announced on September 24, 2026, that it is investigating claims against Cellectis S.A. and its management. The investigation aims to determine if the company and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
The claims stem from a September 14, 2026, announcement by Cellectis. The company stated it would prioritize in vivo gene editing therapies (HEAL-101 and HEAL-201) over CAR-T cell therapies. Concurrently, Cellectis announced plans to discontinue development of its lasme-cel and eti-cel CAR-T cell therapies. Chief Medical Officer Adrian Kilcoyne cited a lack of financial resources and challenging timelines as reasons for discontinuing these specific programs.
Following this news, Cellectis's American Depositary Receipts (ADRs) saw a significant drop, falling $1.27 per ADR, or 40.97%, to close at $1.83 per ADR on September 14, 2026. Investors who have incurred losses and wish to obtain further information or participate in a potential class action are encouraged to contact Pomerantz LLP.
Pomerantz LLP is a law firm with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, specializing in corporate, securities, and antitrust class litigation. The firm has a long-standing history of pursuing cases on behalf of investors affected by securities fraud and corporate misconduct.